Your cart is currently empty!
Prof. George Birkmayer NADH
What is NADH?
NADH is the biological form of hydrogen, which produces energy with the oxygen in the cell.
The biological form of hydrogen NADH occurring in our body reacts with the oxygen present in every living cell to produce essential energy in form of Adenosin Tri Phopshate (ATP). This ATP is used by the cell to produce all components essential for the optimum function of the cell. This include components of the cell nucleus, the mitochondria, the power plants of the cell and the cell membrane. The more ATP a cell has available the better it functions and the longer it lives.
Therefore NADH leads to an extension of the lifespan and the vitality of cells, tissues and organs. In particular the power plants of our cells, the mitochondria are of decisive importance for the regulation of cell division and for the repair of damaged cells. If mitochondria are defect the cells will die.
Prof. George Birkmayer NADH dietary supplement has been in use in EU since 1995.
The effect of NADH (Coenzym 1) on the human organism was first discovered by the Austrian scientist, Professor George Birkmayer, MD, PhD.
He was the first and only to succeed in stabilizing NADH in tablet form and making it bioavailable for the human body. For his NADH formula he obtained more than 50 patents and is regarded internationally as the leading expert for NADH. The effect of his NADH formula has been documented in numerous studies.
Professor Dr. med. Dr. chem. George D. Birkmayer, MD., PhD. (born 1941 in Vienna) has a doctorate in biochemistry as well as in medicine. He became Associate Professor for Cell Biology at the University of Munich in 1988 and Associate Professor for Medical Chemistry at the University of Graz (Austria).
He is author of more than 150 scientific publications and obtains a strong international profile as visiting professor at the Universities in Beijing, Guangzhou, Xi’An, Cornell University (New York) and the American College of Nutrition. He holds world-wide lectures on his research in Oncology, Neurology and Anti-Aging Medicine. In 1999, he was invited to the Annual Denham Harman Lecture of the American Academy for the Advancement of Medicine. Since 1981 he has been a member of the New York Academy of Sciences and, since 2010, Honorary President of the International Academy for Targeted Therapy.